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Remission of lymphoblastic 
leukaemia in an intravascular fluidic 
environment by pliable drug carrier 
with a sliding target ligand
Donghyun Jang1,2, Yeong Mi Lee1,2, Jaehyun Lee3, Junsang Doh3,4 & Won Jong Kim1,2
A polyrotaxane-based nanoconstruct with pliable structure carrying a chemotherapeutic drug was 
developed for targeting circulating lymphoblastic leukaemia cells in a fluidic environment of blood 
vessels in vivo. By introducing lymphoblast targeting aptamer DNA through cyclodextrin, threaded 
in poly(ethylene glycol) as polyrotaxane, target aptamer slides along the long polymeric chain and 
actively search for target ligand, leading to active targeting in dynamic fluidic system which is enhanced 
by up to 6–fold compared with that of control carriers with non–sliding targeting ligands. Moreover, 
the drug carrier was made stimuli-responsive by employing i-motif DNA to selective releases of its 
payload at intracellular acidic condition. These combined features resulted in the effective remission of 
lymphoblastic leukaemia both in vitro and in dynamic blood vessels in vivo.
Lymphoblastic leukaemia is characterized by the uncontrolled production of immature lymphocytes1,2. These 
cancerous lymphocytes, also known as lymphoblasts, spread from the bone marrow where they originate, to var-
ious organs such as the lymph nodes, liver, spleen, or central nerve system through bloodstream3. Of the different 
lymphoblastic leukaemias, acute lymphoblastic leukaemia (ALL) progresses rapidly, and may lead to death within 
several months if not treated appropriately3,4. Chemotherapy, which is widely used treatment for ALL5–7, is associ-
ated with side effects that are often critical to patients. Chemotherapeutic agents tend to target highly proliferating 
cells8, including numerous healthy cells, in the cardiac tissues9, immune system10, liver11, etc. Therefore, intense 
chemotherapy may damage healthy organs, which may be fatal. This is because chemotherapeutic agents are 
passively infused into the body and are not specifically targeted toward cancer cells that circulate in blood vessels.
To overcome these drawbacks, studies have focused on targeted nanoparticle–based drug delivery systems 
with multiple functions12,13. Active targeting can be achieved by conjugating specific ligands such as small mol-
ecules14, proteins15,16 and aptamers17,18 to nanoparticles. This strategy selectively directs nanoparticles toward 
target cells and enhances their cellular uptake to maximize the therapeutic effects of the loaded drug while exert-
ing minimal side effects on normal healthy cells. Unlike the targeting of static solid tumour tissues, targeting of 
rapidly circulating ALL lymphoblasts requires an intelligent drug carrier that can actively search and bind to these 
cells with high binding affinity.
To fulfil the requirement, we used polyrotaxane (PR), which has a unique structure composed of mechanically 
interlocked ring–shaped macrocycles such as cyclodextrin (CD) threaded into a long polymeric backbone19, as a 
base component for developing a pliable drug carrier. CD was modified with an aptamer DNA that has a strong 
binding affinity toward proteins on target cell surface. Aptamer DNA–CD component placed along the polymeric 
polyethylene glycol (PEG) backbone of PR has high degree of sliding freedom20–24. This unique sliding ability 
increases the probability of the aptamer DNA to bind to target molecules on cancer cells and allows attached 
ligands to migrate toward other target molecules to form multimeric bonds, leading to the formation of a robust 
binding between the carrier and target cells21,22,25.
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Along with employing sliding ligand for enhanced targeting ability to target cells, stimuli–responsive behav-
iour that releases drug molecules only in the desired region decreases the toxicity of chemotherapeutic agents in 
non-target region26. Different intracellular conditions such as pH14,27, reductive potential16, enzymes28, and small 
molecules29 have been intensively examined as trigger discharging chemotherapeutic agents in programmed 
environments. We used pH–responsive “i–motif ” DNA30 to induce the stimuli–responsive behaviour of the drug 
carrier31,32. Unique double–stranded DNA (dsDNA) structure formed by the i–motif DNA and its complemen-
tary DNA responds to intracellular acidic environment33 and releases intercalated anti–cancer agent doxorubicin 
(DOX) by inducing its dissociation from the dsDNA27. By integrating these functions, we have developed an 
effective lymphocyte targeting drug carrier in circulating bloodstream environment (Fig. 1).
Results
Synthesis and characterization of pliable drug carrier with a sliding target ligand. The PR–based 
stimuli–responsive flexible drug carrier was developed by modifying CD, supramolecule with cyclic structure, 
and by threading it selectively into PEG. Commercially available α CD was thiolated to α CD–SH by using a 
method described previously (Supplementary Fig. 2)34,35. Next, α CD–SH was conjugated with amine modified 
i–motif DNA or aptamer DNA (Supplementary Table 1) by using a heterobifunctional crosslinker (Supplementary 
Fig. 1a,3). PR and fluorescent PR were prepared using a capping procedure reported previously (Supplementary 
Fig. 1b,c)19. After DNA–CD was threaded into PEG, successful formation of the PR structure was confirmed by 
measuring the increase of fluorescence resonance energy transfer (FRET) signal between cyanine 3 dye (Cy3, 
ex = 550 nm; em = 565 nm) at the 3′ end of i–motif DNA and cyanine 5 (Cy5, ex = 645 nm; em = 660 nm) at the 
end of PEG (Fig. 2a). Formation of polyrotaxane structure restricts the distance between the Cy3-DNA and Cy5-
PEG by mechanically interlocked structure. The inclusion of the Cy3-DNA-CD into PEG enables both dyes to be 
sufficiently close to induce FRET. In contrast, the simple mixture of Cy3-DNA and Cy5-PEG cannot induce close 
approach of two fluorescence dyes. Therefore, the increased FRET signal in 660 nm indicates the successful for-
mation of polyrotaxane structure. Moreover, the successful formation of PR was also confirmed by the molecular 
weight increase of CD-DNA/PR by gel permeation chromatography (GPC) (Supplementary Fig. 4).
Figure 1. Schematic representation of the stimuli-responsive pliable drug carrier with the sliding target 
ligand, and the strategy for targeting lymphoblasts and drug release. 
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PRs each containing i-motif DNA or its complementary DNA were prepared by following the method dis-
cussed above. PRs were annealed to form a polyrotaxane-based nanoconstruct (PRNC) by hybridizing i–motif 
DNA–CD with complementary DNA–CD. This double-stranded DNA formation acts as a crosslinker to form 
the structure of the PRNC. The obtained PRNCs were approximately 400 nm in size as indicated by dynamic 
light scattering (DLS) size measurement data (Supplementary Fig. 5). Transmission Electron Microscopy (TEM) 
image of PRNCs was well correlated to DLS data (Supplementary Fig. 7). The NCs were stable in 10% serum 
condition for 24 h (Supplementary Fig. 6), meaning its suitability for biological applications. The double stranded 
DNA (dsDNA) of the i–motif DNA and complementary DNA dissociates in acidic environment because of the 
formation of characteristic quadruplex structure by the i–motif DNA in this environment, and it was confirmed 
by circular dichroism spectra (Supplementary Fig. 8).
To verify the pH–responsive destruction of the PRNCs (Fig. 2b), the size of the PRNCs was measured by 
performing DLS also in an acidic buffer (Fig. 2c). The size of the PRNCs increased under the acidic condition, 
indicating that dissociation of the dsDNA because of the formation of the i–motif structure in the acidic buffer 
loosened the PRNC structure, thus swelling it slightly. pH-responsive dissociation of PRNC was also confirmed 
by TEM image in different pH condition (Fig. 2d).
Change in the fluorescence of DOX was monitored to study the drug loading and releasing behaviour of 
the PRNCs. Intercalation of DOX into the base pairs of dsDNA quenches its characteristic fluorescence 
(Supplementary Fig. 9). The drug loaded PRNCs underwent haemolysis assay to assure the safety of PRNC 
when treated into biological systems. There was no significant damage occurred to the red blood cells observed 
(Supplementary Fig. 10). Release of loaded drug molecules from the PRNC was monitored at different pH levels. 
Control experiment with a neutral buffer (pH = 7.4) showed only 1% cumulative drug release during 48 h (Fig. 2e, 
blue curve). However, when the pH was decreased to 5.5, a burst release of DOX was observed. Incubation at pH 
5.5 for 1 h released 90% DOX from dsDNA (Fig. 2e, inset), while incubation at the same pH for 48 h released up to 
95% DOX (Fig. 2e, red curve). In contrast, PRNC lacking the i–motif DNA sequence did not significantly release 
DOX upon acidic stimuli (Supplementary Fig. 11). These results confirm that acidic intracellular environment 
triggers the release of intercalated drug from its carrier within a short time.
Evaluation of the targeting ability of PRNC with sliding ligand in cultured cells. While the 
i–motif DNA provides structural rigidity and stimuli–responsive drug delivery by the PRNC, the aptamer DNA 
allows PRNC to target specific cells. In present study, we used protein tyrosine kinase 7 (PTK7) aptamer36,37 
because PTK7 is highly expressed on the membrane of human T lymphoblast cell line CCRF–CEM, a well–
studied model of ALL. PTK7 aptamer is known to induce internalization of the nanoparticles into the cells via 
endocytosis38. By endocytosis, PRNC is internalized by the acidic vesicles called endosome which matures into 
lysosome, which are known to be acidified by ATP-dependent proton pump39,40. This process results in gradual 
decrease of vesicle’s pH up to 4.5–5.0 in lysosomal condition, which can induce the dissociation of i-motif struc-
ture of PRNC. For comparison, PTK7–underexpressing Ramos cell line was used as a control.
Figure 2. Characterization of PRNC. (a) Formation of the PR structure was confirmed by the increase in  
the FRET signal of Cy3 and Cy5. Red line indicates fluorescence signal from polyrotaxane structure of  
Cy3-DNA-CD and Cy5-PEG, while blue line shows that of their simple mixture. (b) Schematic illustration of 
destructed PRNC upon acid stimuli and drug release. (c) Size of PRNC and non i-motif control monitored 
by DLS at different pH. (d) Destruction of PRNC upon acid stimuli is shown by TEM image in different pH 
condition. (e) Cumulative release of DOX from the PRNC was monitored for 48 h in a buffer of pH = 5.5 (red 
curve) and pH = 7.4 (blue curve). Error bar indicated by triplicate experiment.
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We hypothesized that the threaded aptamer DNA–CD will slide along the polymeric PEG chain with a high 
degree of freedom, thus increasing its probability of binding to target molecules on the surface of circulating 
cancer cells and maintaining a stronger binding affinity even in the dynamic environment of the bloodstream. To 
confirm this, we first investigated the uptake efficiency of the PRNC by static cells cultured in vitro. We prepared 
a series of fluorescent Cy5–labelled PRNCs with or without a targeting moiety (T+ /− ), sliding ability (S+ /− ), 
and pH–responsive i–motif DNA sequence (P+ /− ) (Supplementary Table 2). PRNC without sliding ability was 
prepared by introducing excess amount of bare α CDs during PR formation to fill the vacancy in PEG backbone, 
as previously reported that the increase of number of CDs in linear axle restricts the sliding ability of individual 
CDs41–46. The increase of molecular weight confirmed by GPC (Supplementary Fig. 4, red curve) showed success-
ful incorporation of bare CDs in PEG backbone.
Results of in vitro flow cytometry (Fig. 3a, red bar) performed within 4 h after PRNC treatment showed that 
only S(+ )T(+ )P(+ ) PRNC effectively targeted CCRF–CEM cells. Non–sliding S(− )T(+ )P(+ ) PRNC showed 
slightly enhanced cellular uptake; however, this uptake was far low compared with that of S(+ )T(+ )P(+ ) PRNC. 
Other PRNCs lacking the targeting moiety, i.e., S(+ )T(− )P(+ ) or S(− )T(− )P(+ ) PRNC revealed similar target-
ing ability as non–treated negative control PRNCs. These results support our hypothesis that sliding target ligands 
on drug carriers show effective active targeting, which enhances their cellular uptake. However, in control Ramos 
cells, the various Cy5–PRNCs did not exert significantly different effects (Fig. 3a, blue bar) irrespective of their 
sliding properties. This may be because of the underexpression of target molecules on the surface of Ramos cells.
In vivo study of the targeting ability of PRNC in dynamic blood stream. To validate active tar-
geting of PRNCs with the sliding ligand, we conducted a series of experiments in vivo in dynamic mouse blood-
stream environment (Fig. 3b). To minimize graft versus host rejection and confusion during analysis, we used 
immunodeficient Balb/c nude mice in these experiments. We designed a harsh condition by co–introducing both 
target circulating lymphoblasts and drug carriers into the mouse circulatory system. Target lymphoblasts were 
Figure 3. Evaluation of the targeting ability of PRNCs both in vitro and in vivo. (a) The percentage of 
carrier-bound CCRF-CEM and Ramos cells was measured by flow cytometry after treating cells with various 
PRNCs in vitro. (b) Illustration of the procedures of in vivo assessment of the targeting ability of the PRNCs. 
Whole blood samples of PRNC-treated mice were analysed by performing flow cytometry after injecting CFSE-
labelled CCRF-CEM cells, followed by the injection of PRNCs. (c) Distribution of labelled CCRF-CEM cells in 
each quadrant is shown for mice treated with different PRNCs.
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labelled with carboxyfluorescein succinimidyl ester (CFSE), a green fluorescent cell–staining dye, to differentiate 
them from intrinsic mouse mononuclear cells. The stained lymphoblasts were injected intraperitoneally (i.p.), fol-
lowed by the injection of Cy5–PRNCs intravenously (i.v.) after 30 min. Within 4 h after the injection, whole blood 
was obtained from the treated mice and was analysed by performing flow cytometry. By counting the cells located 
in each quadrant of the dot plot, it was observed that 88% labelled lymphoblasts were successfully targeted by 
Cy5–PRNCs in S(+ )T(+ )P(+ ) PRNC-treated mouse (Fig. 3c). However, surprisingly low percentage of labelled 
lymphoblasts (range, 5%~15%) was targeted by Cy5-PRNC in S(− )T(+ )P(+ ), S(+ )T(− )P(+ ) and S(− )T(− )P(+ ) 
PRNC treated mice. Ramos cell-treated mice showed no significant increase in Cy5-PRNC fluorescence signal 
in retrieved cells (Supplementary Fig. 12). These data strongly indicate that our sliding active targeting system 
significantly enhances cellular uptake efficiency of drug carrier even in in vivo fluidic environment.
Anti-cancer effect of PRNC against cultured lymphoblasts. Because enhancement of targeting abil-
ity eventually increases the therapeutic effect of a drug carrier, we examined drug–induced cytotoxicity in cul-
tured cell lines. In addition to active targeting induced by the sliding aptamer DNA, stimuli–responsive drug 
release induced by the i–motif dsDNA is crucial for treating circulating leukemic cells. We treated CCRF–CEM 
and Ramos cells with various PRNCs and monitored the cytotoxic effect of the PRNCs by performing a stand-
ard MTT assay. S(+ )T(+ )P(+ ) PRNC exerted higher cytotoxic effects on CCRF-CEM cells (Fig. 4a) than free 
DOX or other control carriers (See Supplementary Table 3 for IC 50 value). PRNC lacking aptamer or i–motif 
DNA was less effective because it lacked the targeting ability or stimuli–responsive behaviour, respectively. As 
expected, PRNC lacking both aptamer and i–motif DNA had low cytotoxicity. In contrast, free DOX exerted 
higher cytotoxic effect on Ramos cells (Fig. 4b) than other PRNCs. This may be because PRNCs were not effec-
tively transported into cancer cells with assistance of targeting aptamers. Aptamer–modified S(+ )T(+ )P(+ ) 
PRNC exerted the highest cytotoxic effects on Ramos cells because of low but positive expression of PTK7 on 
these cells. However, other PRNCs showed no significant cytotoxicity even at the highest concentration of DOX.
Remission of lymphoblastic leukaemia under intravascular fluidic environment in mouse 
model. Favourable in vitro results obtained using the pH–responsive flexible drug carrier prompted us to 
apply it in vivo in a mouse model. To design an in vivo model for studying the remission of leukaemia in a 
dynamic bloodstream environment, we introduced CCRF–CEM lymphoblasts i.p. into a mouse blood vessel, 
followed by the injection of DOX–loaded PRNCs i.v. after 30 min. At 4 h after the PRNC injection, whole blood 
was obtained from the treated mice and was analysed by Annexin V/propidium iodide (PI) assay. (Figure 5a) We 
observed that S(+ )T(+ )P(+ ) PRNC–treated mice had higher percentage of apoptotic/necrotic CCRF-CEM cells 
as indicated by a bright illumination of Annexin V signal in a fluorescent image, than control mice (Fig. 5b,c,d,e; 
Supplementary Fig. 13). The fluorescence of the region of interest was quantified using an image processing 
software (Supplementary Table 4). These results confirm that the drug delivery system with the sliding targeting 
moiety and stimuli–responsive behaviour effectively killed target lymphoblasts in a fluidic environment in vivo.
Discussion
By adopting the PR as structural basis of the nanoparticle system, we have succeeded in the introduction of linear 
mobility to the targeting moieties. Our experimental results demonstrate that pliability of targeted drug delivery 
carrier has increased the lymphoblast remission both in vitro and in vivo model, as we expected. Especially, in the 
in vivo model we adopted to verify the anticancer activity of our drug carrier has simulated complicated obstacles 
such as fluid velocity, non-specific interactions with other cells and proteins, acute toxicity in organ functions, and 
Figure 4. In vitro cell viability profile of (a) CCRF–CEM and (b) Ramos cells treated with various PRNCs.
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rapid clearance of nanoparticles. These may have disturbed the carrier system to malfunction in practice, but our 
PRNC has overcome these barriers, showing the chance to successful application in more complicated systems.
In summary, we developed a pliable drug delivery carrier by using a polyrotaxane structure that allowed the 
sliding of the targeting ligand, thus enhancing the active targeting efficiency even in an in vivo fluidic bloodstream 
environment. In addition, we used an acid stimuli-responsive system for the programmed delivery of a drug mol-
ecule. As expected, the sliding flexibility of the aptamer DNA greatly increased the adhesion of the PRNC to target 
lymphoblasts. These results suggest that this drug carrier with the sliding target ligand can be used for actively 
targeting circulating cells such as circulating tumour cells in a dynamic bloodstream environment.
Methods
Materials and reagents. Amicon® Ultra-0.5 centrifugal filter device was purchased from Merck Millipore 
(Darmstadt, Germany). Cyanine5 NHS ester was purchased form Lumiprobe Corp. (Hallandale Beach, FL). 
Ficoll-Paque PLUS density gradient was purchased from GE Healthcare (Piscataway, NJ). All other chemicals 
were purchased from Sigma-Aldrich (St. Louis, MO). Purchased commercial reagents were used without further 
purification. All DNAs were purchased from IDT Inc. (Coralville, IA). The details of DNA sequences used in the 
experiments are shown in Table S1.
Figure 5. Evaluation of the cytotoxic ability of PRNCs in vivo by Annexin V–PI apoptosis assay of 
lymphoblasts. (a) Illustration of the overall experimental procedure. Fluorescent microscopic image of 
lymphoblasts (b) not treated, or treated with (c) free DOX, (d) S(+ )T(+ )P(+ ) PRNC, and (e) S(− )T(+ )P(+ ) 
PRNC. (Scale bar = 100 μ m).
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Instrumentations. The 1H-NMR spectrum was obtained using 500 MHz NMR spectrometer (DRX 
500MHZ, Bruker, Germany) and processed using MestReNova (Version 7.1.2, Mestrelab Research S.L., Santiago 
de Compostella, Spain) and mass spectrum was recorded by LTQ Velos dual ion trap mass spectrometer (Thermo 
Scientific, Bremen, Germany). High performance liquid chromatograph (HPLC) and Gel permeation chroma-
tography (GPC) data was obtained by HPLC/GPC system (UFLC Prominence, Shimadzu Corp., Kyoto, Japan) 
and processed with LC Solutions software (Version 1.22 SP1, Shimadzu). Hydrodynamic volumes and surface 
charges of materials were obtained by a Zetasizer Nano (Malvern Instruments, Malvern, UK). TEM image was 
obtained by JEM-1011 (JEOL Inc., Peabody, MA). The fluorescence spectra were measured using a fluorescence 
spectrometer (LS55, Perkin Elmer, Waltham, MA). Flow cytometry analysis data was obtained by FACSCalibur 
(Becton Dickinson, San Jose, CA) and processed with Cell Quest software (Becton Dickinson).
Synthesis of Mono-6-mercapto-6-deoxy-α-cyclodextrin (αCD-SH). α CD-SH was prepared start-
ing from the Mono-6-(p-toluenesulfonyl)-6-deoxy-α -cyclodextrin (α CD-OTs). α CD-OTs (100 mg, 89 μ mol) and 
thiourea (200 mg, 2.63 mmol) were dissolved to 80% aqueous methanol then refluxed at 110 °C with stirring for 
24 h. 10% aqueous sodium hydroxide was then added to the reaction vessel after solvent evaporation with rotary 
evaporator, and the reaction mixture was stirred for 24 h at 40 °C. The pH of reaction mixture was adjusted to 2 by 
adding 1 M hydrochloric acid (aq), 2 mL trichloroethylene was added and stirred for another 10 h in RT. Reaction 
mixture was dried under reduced pressure after removal of trichloroethylene layer. The remaining yellow solid 
was redispersed in 5 mL N,N-dimethylformamide to filter off the precipitate. Solvent of the filtrate was evaporated 
until the mixture became highly viscous, then precipitated by adding excess amount of cold acetone. Precipitate 
was filtered and washed several times with cold acetone and dried under high vacuum with mild heat to remove 
the residual solvents. Product was analysed by 1H NMR (Figure S2) and ESI-MS spectroscopy (Calculated for 
C36H59O29S−Na+: 1010.28, Found 1010.72). The yield was calculated by 1H NMR. (40.9 mg, 46%).
Chemical conjugation of CD to DNAs. DNAs were diluted into 1 mM solution prior to further exper-
iments by adding appropriate amount of buffer solution. Amine-modified DNAs were crosslinked with SPDP 
(Thermo Scientific, Waltham, MA) in prior to the attachment with α CD-SH. In carbonate-Na buffer (0.5 M, 
pH = 9.2), DNA-NH2 was mixed with excess amount of SPDP, then reacted overnight with constant vortexing. 
Reaction mixture was purified and concentrated by centrifugal filter with 3 K MWCO. The concentrated product 
was redispersed in appropriate amount of buffer, then added excess amount of α CD-SH. The reaction mixture 
was again reacted for overnight with constant vortexing, and was purified and concentrated by centrifugal filter 
with 3 K MWCO. Final reaction mixture was lyophilized for further usages. Synthesized DNA-CD was confirmed 
by HPLC analysis (Figure S3).
Formation of polyrotaxane nanoconstruct (PRNC). To synthesize two different types of polyrotax-
anes, we first synthesized poly-pseudorotaxanes. Series of polyrotaxanes which are required for construction 
of various PRNCs possessed 9 equivalent of binding sequence and 1 equivalent of targeting sequence in each 
diamino-poly(ethyleneglycol) (20 KDa, Nanocs Inc. New York, NY). The components were mixed in phosphate 
buffered saline (PBS, Bioneer, Korea) and incubated overnight at 4 °C after sonication for 1 h. For non-sliding 
control groups, we added excess α CD to this mixture, then incubated overnight after sonicating another 1 h. 
Capping procedure followed by adding excess amount of 1-fluoro-2,4-dinitrobenzene then vortexing overnight 
in RT. Reaction mixtures were lyophilized and redispersed in PBS. Synthesized polyrotaxanes were annealed to 
form PRNCs by incubation for 10 min at 90 °C then overnight at 4 °C. Annealed PRNCs were again lyophilized 
and redispersed in PBS to make desired concentration for further experiments.
Serum stability test of PRNC. Stability of PRNC under serum condition was tested by following pro-
cedures. PRNC was incubated in 10% fetal bovine serum (FBS, Hyclone) containing Roswell Park Memorial 
Medium (RPMI-1640, Hyclone) at 37 °C up to 24 h. The hydrodynamic size of PRNC was measured by DLS 
without serum or with serum at 1 h, 2 h, 6 h and 24 h.
Haemolysis test of PRNC. Release of haemoglobin from lysed erythrocytes were evaluated by measur-
ing the UV absorbance in 540 nm wavelength of each samples. Fresh mouse blood was diluted 10 times in PBS 
for haemolysis test. To 380 μ L diluted mouse blood, 20 μ L of each sample either containing Triton X-100, PBS, 
NC Only or 80 μ M DOX (Free DOX, S(+ )T(− )P(+ ) PRNC/DOX, S(+ )T(+ )P(− ) PRNC/DOX) were added. 
These mixtures were incubated at 37 °C for 6 h. Incubated mixtures were centrifuged at 2000 rpm for 15 min, 
then supernatants were collected to measure the absorbance. Triton X-100 was utilized as positive control (100% 
haemolysis).
Drug loading and releasing test. Before the drug loading and releasing tests, fluorescence of DOX 
(ex = 495 nm; ex = 595 nm) was measured at different pH conditions (7.4 and 5.5). Intercalation of DOX in 
i-motif DNA was observed by measuring the intensity of DOX fluorescence after mixing with appropriate con-
centrations of PRNCs. Release of DOX from PRNCs was measured by obtaining fluorescence of single point 
(λ = 595 nm) continuously during 48 h for every 1 min.
Cell culture and animal model. CCRF-CEM is an acute T-lymphoblastic leukaemia cell line derived from 
human peripheral blood, which overexpresses protein tyrosine kinase 7 (PTK-7) on the cell surface. Ramos is a 
Burkitt’s lymphoma cell line which underexpresses PTK-7. Both cell lines were obtained from Korean Cell Line 
Bank (KCLB) and were cultured in Roswell Park Memorial Medium (RPMI-1640, Hyclone) containing 10% 
fetal bovine serum (FBS, Hyclone), 100 U mL-1 penicillin (Hyclone) and 100 μ g mL-1 streptomycin. Cells were 
cultured in 5% CO2 humidified incubator set at 37 °C. Female BALB/c Nude mice were received from POSTECH 
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Biotech Center. All animal experiments in this study were approved by the POSTECH Biotech Center Ethics 
Committee and all methods were performed in accordance with the relevant guidelines and regulations.
In vitro cellular uptake efficiency assay. To test the in vitro cellular uptake efficiency of PRNCs, 
CCRF-CEM or Ramos cells were counted and transferred to 24-well plates at a density of 2 × 105 cells per well in 
1 mL serum-containing media, then Cy5-PRNCs were treated into each well. After 4 h, the treated lymphoblasts 
were retrieved from the well plates and washed several times with cold PBS, then fixed with 10% neutral buffered 
formalin. The fluorescence level of Cy5 in each cell was measured by flow cytometry.
In vivo uptake efficiency study. Prior to the in vivo uptake efficiency test, CCRF-CEM and Ramos cells 
were labelled green using the CellTraceTM CFSE cell proliferation kit (Molecular probes, Eugene, OR) according 
to the protocol of the manufacturer. Labelled CCRF-CEM or Ramos cells (2 × 106 cells) were injected to mice i.p., 
then Cy5-PRNCs were injected i.v. subsequently. After 4 h of circulation, whole blood of sample-treated mice 
was gathered directly from the heart of the mice. Mice were immediately sacrificed after obtaining blood sample. 
Lymphoblasts were separated from mice whole blood by following the standard protocol of Ficoll-Paque PLUS 
density gradient. Lymphoblasts were washed several times with cold PBS, then fixed with 10% neutral buffered 
formalin. The levels of green fluorescence of cells and red fluorescence of Cy5-PRNCs were analysed by flow 
cytometry.
In vitro cytotoxicity test. In vitro cell viability of PRNCs and controls was measured using 3-(4,5-dime
thylthizol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). CCRF-CEM or Ramos cells were counted and trans-
ferred to 96-well plates at a density of 8 × 103 cells per well in 80 μ L serum containing media. Treatment of each 
samples were performed by adding 10 μ L of PBS dispersed samples to the wells. After incubating 18 h, 10 μ L of 
MTT solution (5 mg mL-1) was added in each wells. Cells were then lysed by adding 100 μ L 10% SDS aqueous 
solution (pH = 5.5, Bioneer, Korea) then incubating overnight. The absorbance of formazan salt at 570 nm was 
measured using a microplate reader (VICTOR 3-V Multilabel counter, PerkinElmer, Wellesley, MA).
In vivo remission of lymphoblasts study in mouse model. For the in vivo cytotoxicity assay, 
CCRF-CEM cells (2 × 105 cells) were injected to mice i.p., then samples were injected i.v. subsequently. Similar 
to the methods described in the in vivo uptake efficiency test section, lymphoblasts were separated from mice 
whole blood. Lymphoblasts were thoroughly washed with cold PBS, then treated with Annexin V-FITC Apoptosis 
Detection Kit (Sigma-Aldrich). Treated samples were made into microscopic sample by mounting on microscopic 
slide glass with mounting medium with DAPI (Vector Laboratories, Burlingame, CA). Images were obtained 
from the prepared samples with fluorescent microscope system (Eclipse Ti-E, Nikon, Kobe, Japan) equipped 
with CCD camera (Coolsnap MYO, Photometrics, Tucson, AZ) then processed with NIS-Elements Advanced 
Research software (Version 4.2, Nikon).
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